New hope for advanced breast cancer: YL202 faces off against standard treatments
NCT ID NCT07461454
First seen Mar 11, 2026 · Last updated May 20, 2026 · Updated 8 times
Summary
This phase 3 study tests a new drug, YL202, against standard treatments (like eribulin or capecitabine) in 376 people with advanced HR+/HER2- breast cancer that has not responded to at least one chemotherapy. The main goal is to see if YL202 can delay cancer growth or improve survival. Participants will be randomly assigned to receive either YL202 or a doctor-chosen standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 201321, China
Contact
Conditions
Explore the condition pages connected to this study.